Sofie H Tolmeijer

10PUBLICATIONS
79CO-AUTHORS
Molecular targetsEpigenetics (incl. genome methylation and epigenomics)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Medical biotechnology diagnostics (incl. biosensors)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jul 02, 2026
Germline CDK12 variants in aggressive prostate cancer.

|Jan 23, 2026
Assessing the Detection Power of Genome-Wide Copy Number Variation Profiles in Prostate Cancer Using Simulated Shallow Whole-Genome Sequencing Data.

Samhita Pamidimarri Naga, Peter H J Slootbeek, Sofie H Tolmeijer

|May 27, 2025
Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial.

Edmond M Kwan, Sarah W S Ng, Sofie H Tolmeijer

|Sep 13, 2024
Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working Group.

Alexander W Wyatt, Saskia Litiere, Francois-Clément Bidard

|Feb 28, 2024
Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer.

Nicolette M Fonseca, Corinne Maurice-Dror, Cameron Herberts

|Oct 26, 2023
Therapeutic biomarkers in metastatic castration-resistant prostate cancer: does the state matter?

Peter H J Slootbeek, Sofie H Tolmeijer, Niven Mehra

Pageof 2

Frequent Collaborators

7 joint publications

Niven Mehra

5 joint publications

Alexander W Wyatt

4 joint publications

Marjolijn Ligtenberg

3 joint publications

Cameron Herberts